泰林生物:2025年度财务决算报告

                浙江泰林生物技术股份有限公司

                  2025 年度财务决算报告

  一、2025 年度公司财务报表的审计情况

  浙江泰林生物技术股份有限公司（以下简称“公司”）2025 年财务报表经天健会计师事务所（特殊普通合伙）审计，出具了标准无保留意见的审计报告（天健审〔2026〕1552 号）。会计师的审计意见是：公司财务报表在所有重大方面按照企业会计准则的规定编制，公允反
映了泰林生物公司 2025 年 12 月 31 日的合并及母公司财务状况，以及 2025 年度的合并及母
公司经营成果和现金流量。

  二、主要财务数据和指标

  （一）资产、负债、股东权益情况

                                                                    单位：元

              项目                  2025 年            2024 年        本年比上年增减

 总资产                            958,972,583.39      959,907,928.07              -0.10%

 总负债                            154,681,156.10      139,178,386.25              11.14%

 归属于上市公司股东的净资产        804,291,427.29      820,050,345.31              -1.92%

  （二）经营成果

                                                                        单位：元

              项目                    2025 年            2024 年        本年比上年增减

 营业收入                            339,538,843.84      348,998,253.03              -2.71%

 营业利润                            16,938,093.32      12,398,740.85              36.61%

 归属于上市公司股东的净利润          16,485,445.79      13,050,671.23              26.32%

  （三）现金流情况

                                                                        单位：元

        项目                2025 年                2024 年              同比增减

 经营活动现金流入小计        355,762,860.49        355,695,474.12                  0.02%

 经营活动现金流出小计        308,040,851.05        331,038,859.93                -6.95%

 经营活动产生的现金流          47,722,009.44          24,656,614.19                93.55%
 量净额

 投资活动现金流入小计      1,250,388,212.49        708,157,690.05                76.57%

 投资活动现金流出小计      1,247,985,597.33        750,538,053.63                66.28%

投资活动产生的现金流          2,402,615.16        -42,380,363.58                105.67%
量净额

筹资活动现金流入小计          11,174,000.00          15,645,426.70                -28.58%

筹资活动现金流出小计          51,898,869.94          26,108,435.79                98.78%

筹资活动产生的现金流        -40,724,869.94        -10,463,009.09              -289.23%
量净额

现金及现金等价物净增          8,667,221.07        -28,051,429.88                130.90%
加额

                                            浙江泰林生物技术股份有限公司董事会
                                                              2026 年 3 月 27 日